Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection
K Blom, U Marking, S Havervall, NG Norin… - The Lancet Infectious …, 2022 - thelancet.com
The Lancet Infectious Diseases, 2022•thelancet.com
2 Kimura I, Kosugi Y, Wu J, et al. The SARS-CoV-2 lambda variant exhibits enhanced
infectivity and immune resistance. Cell Rep 2022; 38: 110218. 3 Bruel T, Hadjadj J, Maes P,
et al. Serum neutralization of SARS-CoV-2 omicron sublineages BA. 1 and BA. 2 in patients
receiving monoclonal antibodies. Nat Med 2022; published online March 23. https://doi.
org/10.1038/s41591-022-01792-5. 4 Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy
of antiviral agents against the SARS-CoV-2 omicron subvariant BA. 2. N Engl J Med 2022; …
infectivity and immune resistance. Cell Rep 2022; 38: 110218. 3 Bruel T, Hadjadj J, Maes P,
et al. Serum neutralization of SARS-CoV-2 omicron sublineages BA. 1 and BA. 2 in patients
receiving monoclonal antibodies. Nat Med 2022; published online March 23. https://doi.
org/10.1038/s41591-022-01792-5. 4 Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy
of antiviral agents against the SARS-CoV-2 omicron subvariant BA. 2. N Engl J Med 2022; …
2 Kimura I, Kosugi Y, Wu J, et al. The SARS-CoV-2 lambda variant exhibits enhanced infectivity and immune resistance. Cell Rep 2022; 38: 110218. 3 Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 omicron sublineages BA. 1 and BA. 2 in patients receiving monoclonal antibodies. Nat Med 2022; published online March 23. https://doi. org/10.1038/s41591-022-01792-5. 4 Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA. 2. N Engl J Med 2022; 386: 1475–77.
thelancet.com
